article thumbnail

CannaMD Partners with Releaf App: Tracking Patient Outcomes

CannaMD

Releaf is a free mobile app to help patients track, learn from, and improve their use of medical cannabis. The data that is collected in Releaf App is used for multiple research studies and helps physicians identify what products patients are finding most effective. Patients can learn more by visiting ReleafApp.com.

article thumbnail

Finding ‘Releaf’: Put Data in Your Pipe and Smoke It

The Cannigma

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.

Data 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NORML Publish Book Summarizing Hundreds of Studies Assessing the Safety and Efficacy of Cannabis for Patients ….Now Available on Kindle

Cannabis Law Report

NORML is pleased to announce that its newly updated and revised publication, Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature, 2000 — 2021 , is now available for download on the Kindle app. Proceeds from the purchase of the new book directly fund NORML’s cannabis advocacy efforts.

Safety 52
article thumbnail

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

TheAnswerPage

Are you able to answer your patients’ medical marijuana questions? We also provide free downloadable resources: ‘The Endocannabinoid System and Medical Marijuana in 15 minutes!’ and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ Unfortunately, this did not occur.

article thumbnail

Medxtractor Doubles Down on B2B Licensing & mHealth

Cannabis Law Report

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE: Source: Data Bridge.

article thumbnail

MedXtractor Fills a Key Gap in Mental Health Treatments

Cannabis Law Report

Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. of patients with major depressive disorder, 92.7% of patients with bipolar disorder, 71% of patients with generalized anxiety disorder, and 97.8% of patients with social anxiety disorder. Building the Data Backend.

article thumbnail

FDA Publish Article “5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC”

Cannabis Law Report

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,

THC 105